Business Context and Reporting Period
This Form 8-K is a current report filed by PharmAthene, Inc. (not Altimmune, Inc.) on November 6, 2015. The filing serves to announce the company's financial and operational results for the quarter ended September 30, 2015, as detailed in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet for the 8-K filing and does not contain specific numerical data. Consequently, values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this document. These figures are contained within the referenced press release (Exhibit 99.1), which is not included in the input text.
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. It only confirms that results for the quarter ended September 30, 2015, were announced.
Guidance, Outlook, and Risks
The document does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. It explicitly states that the information in the report and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except as expressly set forth.
Investor Verification Checklist
- Verify the correct registrant name is PharmAthene, Inc., as the input metadata incorrectly listed Altimmune, Inc.
- Locate and review Exhibit 99.1 (the press release dated November 6, 2015) to obtain actual financial figures for the quarter ended September 30, 2015.
- Confirm the specific operational milestones or clinical trial updates mentioned in the press release, as the 8-K text only references their existence.